S&P 500   3,093.34 (-0.74%)
DOW   26,745.06 (-0.79%)
QQQ   214.04 (-1.13%)
AAPL   284.89 (-2.65%)
FB   194.92 (-1.16%)
GOOGL   1,367.74 (-1.63%)
CGC   19.33 (-2.47%)
MU   52.83 (+0.88%)
TSLA   723.94 (-7.05%)
AMD   45.76 (-3.64%)
T   36.65 (-1.21%)
NFLX   388.98 (+2.57%)
BAC   30.26 (-1.21%)
DIS   122.63 (-0.59%)
GILD   73.39 (-1.75%)
S&P 500   3,093.34 (-0.74%)
DOW   26,745.06 (-0.79%)
QQQ   214.04 (-1.13%)
AAPL   284.89 (-2.65%)
FB   194.92 (-1.16%)
GOOGL   1,367.74 (-1.63%)
CGC   19.33 (-2.47%)
MU   52.83 (+0.88%)
TSLA   723.94 (-7.05%)
AMD   45.76 (-3.64%)
T   36.65 (-1.21%)
NFLX   388.98 (+2.57%)
BAC   30.26 (-1.21%)
DIS   122.63 (-0.59%)
GILD   73.39 (-1.75%)
S&P 500   3,093.34 (-0.74%)
DOW   26,745.06 (-0.79%)
QQQ   214.04 (-1.13%)
AAPL   284.89 (-2.65%)
FB   194.92 (-1.16%)
GOOGL   1,367.74 (-1.63%)
CGC   19.33 (-2.47%)
MU   52.83 (+0.88%)
TSLA   723.94 (-7.05%)
AMD   45.76 (-3.64%)
T   36.65 (-1.21%)
NFLX   388.98 (+2.57%)
BAC   30.26 (-1.21%)
DIS   122.63 (-0.59%)
GILD   73.39 (-1.75%)
S&P 500   3,093.34 (-0.74%)
DOW   26,745.06 (-0.79%)
QQQ   214.04 (-1.13%)
AAPL   284.89 (-2.65%)
FB   194.92 (-1.16%)
GOOGL   1,367.74 (-1.63%)
CGC   19.33 (-2.47%)
MU   52.83 (+0.88%)
TSLA   723.94 (-7.05%)
AMD   45.76 (-3.64%)
T   36.65 (-1.21%)
NFLX   388.98 (+2.57%)
BAC   30.26 (-1.21%)
DIS   122.63 (-0.59%)
GILD   73.39 (-1.75%)
Log in

NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Forecast & News

$94.77
-0.01 (-0.01 %)
(As of 02/27/2020 12:57 PM ET)
Today's Range
$90.91
Now: $94.77
$95.04
50-Day Range
$96.14
MA: $105.48
$113.92
52-Week Range
$94.43
Now: $94.77
$141.86
Volume1.49 million shs
Average Volume2.28 million shs
Market Capitalization$20.98 billion
P/E Ratio8.83
Dividend YieldN/A
Beta1.68
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.99 billion
Cash Flow$11.52 per share
Book Value$50.91 per share

Profitability

Net Income$2.40 billion

Miscellaneous

Employees3,082
Market Cap$20.98 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.


Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings data on Thursday, January, 30th. The biopharmaceutical company reported $2.71 EPS for the quarter, topping the Zacks' consensus estimate of $2.60 by $0.11. The biopharmaceutical company had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.32 billion. Alexion Pharmaceuticals had a return on equity of 21.29% and a net margin of 48.17%. The firm's quarterly revenue was up 22.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.14 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share guidance of $10.65-$10.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.96. The company issued revenue guidance of $5.50-$5.56 billion, compared to the consensus revenue estimate of $5.51 billion.

What price target have analysts set for ALXN?

20 Wall Street analysts have issued 1 year price targets for Alexion Pharmaceuticals' shares. Their forecasts range from $131.00 to $180.00. On average, they expect Alexion Pharmaceuticals' share price to reach $149.95 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

What is the consensus analysts' recommendation for Alexion Pharmaceuticals?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 4 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Has Alexion Pharmaceuticals been receiving favorable news coverage?

News articles about ALXN stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Alexion Pharmaceuticals.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Celgene (CELG), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), Visa (V), Broadcom (AVGO) and Biogen (BIIB).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 56)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
  • Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)
  • Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62)

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wealth Quarterback LLC (6.93%), FMR LLC (6.64%), State Street Corp (4.95%), Renaissance Technologies LLC (1.69%), Artisan Partners Limited Partnership (1.49%) and Geode Capital Management LLC (1.44%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Which institutional investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Franklin Resources Inc., Partner Fund Management L.P., FIL Ltd, Sei Investments Co., Jennison Associates LLC and Strs Ohio. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker and Indrani Lall Franchini. View Insider Buying and Selling for Alexion Pharmaceuticals.

Which institutional investors are buying Alexion Pharmaceuticals stock?

ALXN stock was bought by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, AQR Capital Management LLC, Renaissance Technologies LLC, Bank of Montreal Can, LSV Asset Management, Thrivent Financial for Lutherans, Man Group plc and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $94.82.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $20.99 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe.View Additional Information About Alexion Pharmaceuticals.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]


MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,208 (Vote Outperform)
Underperform Votes:  714 (Vote Underperform)
Total Votes:  1,922
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel